Grigoriadis Dimitri E. 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Feb 2, 2022
Insider Transaction Report
Form 4
Grigoriadis Dimitri E.
Vice President, Research
Transactions
- Award
Restricted Stock Unit
2022-01-31+4,746→ 4,746 total→ Common Stock (4,746 underlying) - Award
Stock Option
2022-01-31+32,319→ 32,319 totalExercise: $79.02Exp: 2032-01-31→ Common Stock (32,319 underlying)
Footnotes (3)
- [F1]Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- [F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F3]The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of January 31, 2023, January 31, 2024, January 31, 2025, and January 31, 2026.